AIM ImmunoTech Inc. has announced that the clinical successes of its drug Ampligen in oncology will be highlighted at the upcoming 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland. The presentations will cover various aspects, including ongoing clinical programs in late-stage pancreatic cancer and Ampligen's potential therapeutic effects on multiple cancer types. Additionally, there will be discussions on the cellular and molecular mechanisms of Ampligen in oncology and its potential as a therapy for endometriosis. The presentations will feature data from the Phase 2 DURIPANC study, which is evaluating the combination of Ampligen and AstraZeneca's durvalumab in treating metastatic pancreatic cancer. Preliminary data suggest Ampligen may improve survival outcomes in this context. Results are to be presented at the symposium.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。